DMAC — DiaMedica Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401040 ·
Last close
$6.32
Market Cap
$340.54M
52W High
$8.52
52W Low
$5.24
ADV30
243,243
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,482,000 | -10,042,000 | 53,080,000 | 4,868,000 | 5,845,000 |
| Dec 2025 | 0 | — | -9,213,000 | -8,740,000 | 61,371,000 | 15,647,000 | 5,260,000 |
| Sep 2025 | 0 | — | -9,033,000 | -8,620,000 | 57,047,000 | 3,326,000 | 5,425,000 |
| Jun 2025 | 0 | — | -8,007,000 | -7,699,000 | 31,470,000 | 4,109,000 | 4,300,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,062,000
Investing CF
$-2,192,000
Financing CF
$43,876,000
CapEx
$-40,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-172,768,000
Inventory
—
Receivables
$258,000
ST Investments
$44,243,000
EBIT TTM
$-34,397,000
Pretax Income TTM
$-32,738,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,397,000 | -32,766,000 | 61,371,000 | 5,260,000 | — | -29,062,000 |
| Dec 2024 | 0 | -26,681,000 | -24,444,000 | 46,345,000 | 5,627,000 | — | -22,076,000 |
| Dec 2023 | 0 | -21,267,000 | -19,381,000 | 54,160,000 | 3,103,000 | — | -18,728,000 |
| Dec 2022 | 0 | -14,001,000 | -13,676,000 | 34,395,000 | 2,568,000 | — | -11,511,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LAB | STANDARD BIOTOOLS INC. | $342.10M | $0.87 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $342.87M | $3.14 | — |
| AKBA | Akebia Therapeutics, Inc. | $338.01M | $1.26 | — |
| UPB | Upstream Bio, Inc. | $348.83M | $6.41 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $332.44M | $4.67 | — |
News headlines (Yahoo Finance, 1h cache)
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 20:30 · Yahoo
DiaMedica (DMAC) Q4 2025 Earnings Transcript
2026-06-01 20:17 · Yahoo
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans
2026-05-10 14:59 · Yahoo
DiaMedica Therapeutics Q1 Earnings Call Highlights
2026-05-07 17:42 · Yahoo
DiaMedica Therapeutics Inc. Q1 2026 Earnings Call Summary
2026-05-07 12:30 · Yahoo
RedChip's Biotech Virtual Investor Conference Replays Now Available
2026-04-21 19:00 · Yahoo
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
2026-04-16 16:04 · Yahoo
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
2026-04-07 15:00 · Yahoo
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
2026-03-31 19:01 · Yahoo
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary
2026-03-31 16:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.